Drugs / Endo-Clot(TM)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02732483 | Apr 2016 → Apr 2018 | — | Yonsei University | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02625792 | Dec 2015 → Oct 2016 | ulcer disease | Yonsei University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Endo-Clot(TM) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02625792 ↗ |
| Known as | Endo-Clot | “There are currently three powders commercially available: hemostatic agent TC-325 (Hemospray(®)), EndoClot™ polysaccharide hemostatic system, and Ankaferd Bloodstopper(®).” PMID 25133029 ↗ Aug 20141“After patients treated with ESD, Hemostatic power was applied on the post-resection surface by Endo-Clot™ system.” NCT02625792 ↗ |
| Modality | Other / unclassified | “EndoClot™ polysaccharide hemostatic system” PMID 25133029 ↗ Aug 2014 |
| Route | Topical | “Hemostatic power was applied on the post-resection surface” NCT02625792 ↗ |